[1] 国家药典委员会.中华人民共和国药典(一部)[M]. 北京:中国医药科技出版社,2015:331-332. [2] Wang G S.Medical uses of mylabris in ancient China and recent studies[J]. J Ethnopharmacol, 1989, 26(2):147-162. [3] 孙震晓,李家实.去甲斑蝥素抗肿瘤研究热点[J].西北药学杂志,1998,13(5):227-229. [4] 洪兴福, 李宝赛, 孙震晓. 去甲斑蝥素对体外微管蛋白聚合的抑制作用[J]. 中国药理学与毒理学杂志, 2012, 26(5):630-634. [5] Zhao J, Guan X W, Chen S W, et al.Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors[J]. Bioorg Med Chem Lett, 2015, 25(2):363-366. [6] Hou T, Xiao Z, Li Y, et al.Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression[J]. Am J Transl Res, 2015, 7(11):2199-2211. [7] Wu M H, Chiou H L, Lin C L, et al.Induction of endoplasmic reticulum stress and mitochondrial dysfunction dependent apoptosis signaling pathway in human renal cancer cells by norcantharidin[J]. Oncotarget, 2018, 9(4):4787-4797. [8] Lv H, Li Y, Du H, et al.The synthetic compound norcantharidin induced apoptosis in mantle cell lymphoma in vivo and in vitro through the PI3K-Akt-NF-κB signaling pathway[J]. Evid Based Complement Alternat Med, 2013, 2013(2):461-487. [9] 陈静,崔宝弟,孙震晓.去甲斑蝥素作用早期对人肝癌细胞活性氧及NF-E2相关因子2/抗氧化反应元件信号通路的激活[J].中国药理学与毒理学杂志,2017,31(1):94-100. [10] Wu Y, Cao C M, Wang H Q, et al.Norcantharidin downregulates programmed cell death 4 expression in human gastric cancer cells[J]. Chin J Pharmacol Toxicol, 2013, 27(4):622-628. [11] Liu X H, Blazsek I, Comisso M, et al.Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells[J]. Eur J Cancer, 1995, 31(6):953-963. [12] 郑丹, 沙启明, 王剑青,等. 去甲斑蝥素对环磷酰胺诱导的白细胞减少症模型大鼠骨髓造血功能的影响[J]. 中国实验血液学杂志, 2015, 23(3):826-831. [13] Hart M E, Chamberlin A R, Walkom C, et al.Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity[J]. Bioorg Med Chem, 2004, 14(8):1969-1973. [14] Robertson M J, Gordon C P, Gilbert J, et al.Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity[J]. Bioorg Med Chem Lett, 2011, 19(18):5734-5741. [15] Han H W, Qiu H Y, Hu C, et al.Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs[J]. Bioorg Med Chem Lett, 2016, 26(14):3237-3242. [16] Tang Z B, Chen Y Z, Zhao J, et al.Conjugates of podophyllotoxin and norcantharidin as dual inhibitors of topoisomeraseⅡ and protein phosphatase 2A[J]. Eur J Med Chem, 2016, 10(123):568-576. [17] Ho Y P, To K, Au-Yeung S, et al.Potential New Antitumor Agents from an Innovative Combination of Demethylcantharidin, a Modified Traditional Chinese Medicine, with a Platinum Moiety[J]. J Med Chem, 2001, 44(13):2065-2068. [18] Zhao C, Li C, Wang X, et al.The regio-selective synthesis of 10-hydroxy camptothecin norcantharidin conjugates and their biological activity evaluationin vitro[J]. R Soc Open Sci, 2018, 5(6):172317 [19] Wang X H, Yang F H, Zhao C K, et al.Sealed tube promoted coupling of camptothecin and norcantharidin acid ester and their preliminary biological activity evaluation in vitro[J]. Med Che Res, 2018, 27(2):406-411. [20] 李亚男,迟金华,刘万顺,等.去甲斑蝥素-壳聚糖缓释制剂长期毒性研究[J].中国海洋药物,2017,36(5):33-41 [21] 范潇婷,于睿鹏,董瑞娟,等.斑蝥素及去甲斑蝥素对小鼠毒性靶器官的影响[J].中国实验方剂学杂志,2017,23(15):118-123. [22] Wang X, Gu Z, Li G, et al.Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa[J]. Oncol Rep, 2014, 32(2):716-722. [23] 李子木,孙震晓.伊立替康联合去甲斑蝥素对人胃癌细胞作用的考察及协同作用机制研究[J].生物化学与生物物理进展,2015,42(2):169-182 [24] 曹秋菊, 田志华, 孙晟,等. 人胃癌BGC-823细胞中去甲斑蝥素抑癌作用机理的蛋白质组学研究[J]. 生物化学与生物物理进展, 2009, 36(9):1114-1121. [25] Dan J, Yan W, Cui J S, et al.Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway[J]. Oncol Rep, 2018,40(2): 609-620. [26] Du H F, Yu L J, Meng Y F, et al.Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts[J]. Leuk Lymphoma, 2013, 54(3):607-618. [27] Sun C Y, Zhu Y, Li X F, et al.Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling[J]. Oncotarget, 2017, 8(70):114945-114955. [28] 李宗宪, 刘秀萍, 刘厚强. 去甲斑蝥素联合FOLFOX4方案治疗晚期大肠癌40例[J]. 山东医药, 2010, 50(46):109. [29] 赵悦友, 杨洪业, 刘桂仙,等. 去甲斑蝥素联合化疗治疗晚期肝癌[J]. 中国肿瘤临床与康复, 1997,4(3):75. [30] 刘裕民, 张景勍, 游智梅,等. 去甲斑蝥素和吴茱萸碱联合处理对HepG2人肝癌细胞生长的抑制作用[J]. 细胞与分子免疫学杂志, 2014, 30(8):824-828. [31] 刘世芬, 丁玉峰, 牛建一,等. 去甲斑蝥素联合紫杉醇对非依赖前列腺癌细胞的抑制作用[J]. 中国临床药理学杂志, 2017,33(15):1457-1459. [32] Wang D, Yang C, Wang Z, et al.Norcantharidin combined with Coix seed oil synergistically induces apoptosis and inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation[J]. Sci Rep, 2017, 7(1):9373. [33] 初玉平, 沈琳, 白羽. 去甲斑蝥素联合中药治疗老年晚期肝癌的疗效观察[J]. 世界中西医结合杂志, 2012, 7(9):765-767. [34] 李在林. 去甲斑蝥素与淫羊藿联合对原发性肝癌的临床效果分析[J].中外医学研究,2015,13(26):8-9. [35] 刘安, 单德琴. 肝复乐与去甲斑蝥素联用治疗中晚期肝癌[J]. 内蒙古中医药, 1998,4(36):6. [36] Mo L. Xin J W, Xiao J S, et al., Norcantharidin enhances antitumor immunity of GM-CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells[J]. Cancer Sci, 2018,109(7):2109-2118. |